Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.

Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.

Pokaži ostale verzije (1)

Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinases (DYRKs) play key roles in brain development, regulation of splicing, and apoptosis, and are potential drug targets for neurodegenerative diseases and cancer. We present crystal structures of one representative member of each DYRK subfam...

Bibliografski detalji
Glavni autori:	Soundararajan, M, Roos, A, Savitsky, P, Filippakopoulos, P, Kettenbach, A, Olsen, J, Gerber, SA, Eswaran, J, Knapp, S, Elkins, J
Format:	Journal article
Jezik:	English
Izdano:	2013

Slični predmeti

Structures of down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition
od: Soundararajan, M, i dr.
Izdano: (2013)

Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases.
od: Myrianthopoulos, V, i dr.
Izdano: (2013)

Rapid determination of multiple linear kinase substrate motifs by mass spectrometry.
od: Kettenbach, A, i dr.
Izdano: (2012)

Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation.
od: Filippakopoulos, P, i dr.
Izdano: (2008)

Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation.
od: Filippakopoulos, P, i dr.
Izdano: (2008)

UnPAKing the class differences among p21-activated kinases.
od: Eswaran, J, i dr.
Izdano: (2008)

Structure and functional characterization of the atypical human kinase haspin.
od: Eswaran, J, i dr.
Izdano: (2009)

Structure and functional characterization of the atypical human kinase haspin.
od: Eswaran, J, i dr.
Izdano: (2009)

Differential regulation of expression of the protein kinases DYRK1A and DYRK1B in cancer cells
od: Vincent Andreas Vorwerk, i dr.
Izdano: (2024-10-01)

Leucettines, a family of pharmacological inhibitors of DYRKs and CLKs kinases derived from the marine sponge Leucettamine B
od: Tahtouh, T, i dr.
Izdano: (2012)

SH2 domains: modulators of nonreceptor tyrosine kinase activity.
od: Filippakopoulos, P, i dr.
Izdano: (2009)

Insights into protein kinase regulation and inhibition by large scale structural comparison.
od: Eswaran, J, i dr.
Izdano: (2010)

Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy
od: Nikolaos Kokkorakis, i dr.
Izdano: (2024-04-01)

Structure and substrate specificity of the Pim-1 kinase
od: Bullock, A, i dr.
Izdano: (2005)

Structure and substrate specificity of the Pim-1 kinase.
od: Bullock, A, i dr.
Izdano: (2005)

Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs
od: Eswaran, J, i dr.
Izdano: (2007)

DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain
od: Samira Abu Jhaisha, i dr.
Izdano: (2017-07-01)

Insights from the protein interaction Universe of the multifunctional “Goldilocks” kinase DYRK1A
od: Varsha Ananthapadmanabhan, i dr.
Izdano: (2023-10-01)

The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells
od: Bernard Khor, i dr.
Izdano: (2015-05-01)

Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs.
od: Eswaran, J, i dr.
Izdano: (2007)

Selective inhibition of the kinase DYRK1A by targeting its folding process
od: Isao Kii, i dr.
Izdano: (2016-04-01)

Identification of the Kinase-Substrate Recognition Interface between MYPT1 and Rho-Kinase
od: Mutsuki Amano, i dr.
Izdano: (2022-01-01)

Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
od: Akué-Gédu, R, i dr.
Izdano: (2009)

DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.
od: Christophe Noll, i dr.
Izdano: (2009-10-01)

Structure of dystrophia myotonica protein kinase.
od: Elkins, J, i dr.
Izdano: (2009)

Structure of dystrophia myotonica protein kinase.
od: Elkins, J, i dr.
Izdano: (2009)

Crystal Structure of Sphingosine Kinase 1 with PF-543.
od: Wang, J, i dr.
Izdano: (2014)

Dual specificity kinase DYRK3 regulates cell migration by influencing the stability of protrusions
od: Martina Ramella, i dr.
Izdano: (2024-04-01)

An atypical DYRK kinase connects quorum-sensing with posttranscriptional gene regulation in Trypanosoma brucei
od: Mathieu Cayla, i dr.
Izdano: (2020-03-01)

DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis
od: Agata Barzowska, i dr.
Izdano: (2021-08-01)

Fragment screening of cyclin G-associated kinase by weak affinity chromatography.
od: Meiby, E, i dr.
Izdano: (2012)

Fragment screening of cyclin G-associated kinase by weak affinity chromatography
od: Meiby, E, i dr.
Izdano: (2012)

Evolution of protein kinase substrate recognition at the active site.
od: David Bradley, i dr.
Izdano: (2019-06-01)

Functional analysis of the Aspergillus fumigatus kinome identifies a druggable DYRK kinase that regulates septal plugging
od: Norman van Rhijn, i dr.
Izdano: (2024-06-01)

Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture.
od: Eswaran, J, i dr.
Izdano: (2008)

Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
od: Tahtouh, T, i dr.
Izdano: (2012)

DYRK-family kinases regulate Candida albicans morphogenesis and virulence through the Ras1/PKA pathway
od: Jessie MacAlpine, i dr.
Izdano: (2023-12-01)

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
od: Katharina Rüben, i dr.
Izdano: (2015-01-01)

Analysis of conditions affecting auto-phosphorylation of human kinases during expression in bacteria.
od: Shrestha, A, i dr.
Izdano: (2012)

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
od: Miduturu, C, i dr.
Izdano: (2011)